TruSight Oncology 500 Portfolio by Illumina: Comprehensive Insights, Personalized Solutions
In the pursuit of personalized oncology, the TruSight Oncology 500 Portfolio from Illumina stands as a beacon of innovation, delivering a comprehensive suite of genomic solutions. Among the key offerings is the AmpliSeq module, empowering individuals and families with detailed BRCA1/2 mutation analysis for precise cancer risk assessment and personalized treatment strategies.
The AmpliSeq module within the TruSight Oncology 500 Portfolio is more than a test; it’s a transformative tool that tailors oncological treatments and assesses hereditary mutation risks within families. By offering unparalleled insights, it empowers healthcare providers and individuals to make informed decisions, ushering in a new era of personalized healthcare.
Whether you seek diagnostic support for precise treatment or predictive analysis for family-wide risk assessments, AmpliSeq is your ally in the journey towards more informed and personalized healthcare decisions. Illuminate the path to a healthier future with TruSight Oncology 500 Portfolio by Illumina.
Comprehensive BRCA1/2 Analysis:
AmpliSeq goes beyond conventional testing, employing Next-Generation Sequencing (NGS) to provide in-depth analysis of BRCA1/2 germline mutations. This information is pivotal in guiding targeted therapies and informing decisions on surgical interventions for optimal cancer management.
Conducted directly on patients, AmpliSeq serves as a powerful tool for determining the most effective precision oncology treatment. It unravels the genetic intricacies of individual cases, contributing to tailored and effective therapeutic approaches.
Predictive Analysis for Families:
AmpliSeq extends its impact to family members, conducting predictive analysis to assess the likelihood of inherited mutation risks. This not only aids in proactive healthcare planning but also plays a crucial role in identifying potential risks within family networks.
- Tissue Samples for Patients
- Blood Samples for Family Members
These varied examination types, coupled with a versatile range of sample sources, underscore the adaptability and inclusivity of AmpliSeq within the TruSight Oncology 500 Portfolio.